Advanced search
Publication Cover
Immunological Medicine Volume 42, 2019 - Issue 4
Submit an article Journal homepage
1,715
Views
3
CrossRef citations to date
0
Altmetric
Original Article

Pharmacokinetic properties of Privigen® in Japanese patients with primary immunodeficiency

Tomohiro MorioDepartment of Pediatrics and Developmental Biology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan; Correspondence[email protected]
,
Gautam BahetiCSL Behring LLC, King of Prussia, PA, USA;
,
Michael A. TortoriciCSL Behring LLC, King of Prussia, PA, USA;
,
Jutta HofmannCSL Behring AG, Bern, Switzerland
&
Mikhail A. RojavinCSL Behring LLC, King of Prussia, PA, USA;
Pages 162-168 | Received 31 Oct 2019, Accepted 23 Nov 2019, Published online: 17 Dec 2019

References

  • Bousfiha A, Jeddane L, Al-Herz W, et al. The 2015 IUIS phenotypic classification for primary immunodeficiencies. J Clin Immunol. 2015;35(8):727–738.
  • Picard C, Al-Herz W, Bousfiha A, et al. Primary immunodeficiency diseases: an update on the classification from the International Union of Immunological Societies Expert Committee for Primary Immunodeficiency 2015. J Clin Immunol. 2015;35(8):696–726.
  • Wood P, Stanworth S, Burton J, et al. Recognition, clinical diagnosis and management of patients with primary antibody deficiencies: a systematic review. Clin Exp Immunol. 2007;149(3):410–423.
  • McCusker C, Upton J, Warrington R. Primary immunodeficiency. Allergy Asthma Clin Immunol. 2018;14(S2):61.
  • Bousfiha A, Jeddane L, Picard C, et al. The 2017 IUIS phenotypic classification for primary immunodeficiencies. J Clin Immunol. 2018;38(1):129–143.
  • Ortega-López MC, Garay J, Pinilla ML. Efficacy, safety and quality of life in patients receiving subcutaneous IgG treatment: experience in Bogotá, Colombia. Immunotherapy. 2018;10(10):861–869.
  • Modell V, Knaus M, Modell F, et al. Global overview of primary immunodeficiencies: a report from Jeffrey Modell Centers worldwide focused on diagnosis, treatment, and discovery. Immunol Res. 2014;60(1):132–144.
  • Ballow M. Primary immunodeficiency disorders: antibody deficiency. J Allergy Clin Immunol. 2002;109(4):581–591.
  • Espanol T, Prevot J, Drabwell J, et al. Improving current immunoglobulin therapy for patients with primary immunodeficiency: quality of life and views on treatment. Patient Prefer Adherence. 2014;8:621–629.
  • Jolles S, Orange JS, Gardulf A, et al. Current treatment options with immunoglobulin G for the individualization of care in patients with primary immunodeficiency disease. Clin Exp Immunol. 2015;179(2):146–160.
  • Krivan G, Jolles S, Granados EL, et al. New insights in the use of immunoglobulins for the management of immune deficiency (PID) patients. Am J Clin Exp Immunol. 2017;6(5):76–83.
  • Aghamohammadi A, Moin M, Farhoudi A, et al. Efficacy of intravenous immunoglobulin on the prevention of pneumonia in patients with agammaglobulinemia. FEMS Immunol Med Microbiol. 2004;40(2):113–118.
  • Kearns S, Kristofek L, Bolgar W, et al. Clinical profile, dosing, and quality-of-life outcomes in primary immune deficiency patients treated at home with immunoglobulin G: data from the IDEaL Patient Registry. J Manag Care Spec Pharm. 2017;23:400–406.
  • Albin S, Cunningham-Rundles C. An update on the use of immunoglobulin for the treatment of immunodeficiency disorders. Immunotherapy. 2014;6(10):1113–1126.
  • Privigen®, Immune Globulin Intravenous (Human), 10% Liquid; CSL Behring AG, US PI, September. 2017 [cited 2019 Oct 28]. Available from: https://www.fda.gov/media/83304/download
  • Privigen®100 mg/ml solution for infusion, EU, Summary of product characteristics, 2017 [cited 2019 Oct 28]. Available from: https://www.ema.europa.eu/en/documents/product-information/privigen-epar-product-information_en.pdf
  • CSL Behring. Japan’s Ministry of Health, Labour and Welfare Approves CSL Behring Immunoglobulins to Treat Patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP). [cited 2019 Sep 11]. Available from: https://www.cslbehring.com/newsroom/2019/20190326-japan-cidp.
  • Sleasman JW, Duff CM, Dunaway T, et al. Tolerability of a new 10% liquid immunoglobulin for intravenous use, Privigen, at different infusion rates. J Clin Immunol. 2010;30(3):442–448.
  • Bolli R, Woodtli K, Bartschi M, et al. L-Proline reduces IgG dimer content and enhances the stability of intravenous immunoglobulin (IVIG) solutions. Biologicals. 2010;38(1):150–157.
  • Stein MR, Nelson RP, Church JA, et al. Safety and efficacy of Privigen, a novel 10% liquid immunoglobulin preparation for intravenous use, in patients with primary immunodeficiencies. J Clin Immunol. 2009;29(1):137–144.
  • Tortorici MA, Lawo JP, Weide R, et al. Privigen(R) has similar pharmacokinetic properties in primary and secondary immune deficiency. Int Immunopharmacol. 2019; 66:119–126.
  • Wasserman RL, Church JA, Peter HH, et al. Pharmacokinetics of a new 10% intravenous immunoglobulin in patients receiving replacement therapy for primary immunodeficiency. Eur J Pharm Sci. 2009;37(3-4):272–278.
  • Eijkhout HW, van Der Meer JW, Kallenberg CG, et al. The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia. A randomized, double-blind, multicenter crossover trial. Ann Intern Med. 2001;135(3):165–174.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.